Role of positron emission tomography/computed tomography (PET/CT) in head and neck cancer

Radiologic Clinics of North America

Volumn 51, Issue 5, 2013, Pages 881-893

  Escott, Edward J ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

FDG; Head and neck cancer; PET CT; Prognosis; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SALIVARY GLAND CANCER; SENSITIVITY AND SPECIFICITY; THYROID CANCER;

FDG; HEAD AND NECK CANCER; PET/CT; PROGNOSIS; STAGING;

CONTRAST MEDIA; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 84883462696     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2013.05.002     Document Type: Review

References (49)

1. Johnson N.W., Amarasinghe H.K. Epidemiology and aetiology of head and neck cancers. Head and neck cancer: Multimodality management 2011, 1-40. Springer Science+Business Media, New York. J. Berner (Ed.).
2. Xu G.Z., Guan D.J., He Z.Y. (18)FDG-PET/CT for detecting distant metastases and second primary cancers in patients with head and neck cancer. A meta-analysis. Oral Oncol 2011, 47(7):560-565.
3. Fletcher J.W., Djulbegovic B., Soares H.P., et al. Recommendations on the use of 18F-FDG PET in oncology. JNucl Med 2008, 49:480-508.
4. Som P.M. Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. AJR Am J Roentgenol 1992, 158(5):961-969.
5. Ozer E., Naiboǧlu B., Meacham R., et al. The value of PET/CT to assess clinically negative necks. Eur Arch Otorhinolaryngol 2012, 269(11):2411-2414.
6. Fukui M.B., Blodgett T.M., Snyderman C.H., et al. Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics 2005, 25(4):913-930.
7. Korn R.L., Coates A., Milstine J. The role of glucose and FDG metabolism in the interpretation of PET studies. PET and PET/CT: a clinical guide 2009, 22-29. Thieme Medical Publishing, New York, Chapter 3. 2nd edition. E. Lin, A. Alavi (Eds.).
8. Escott E.J. Positron emission tomography-computed tomography protocol considerations for head and neck cancer imaging. Semin Ultrasound CT MR 2008, 29(4):263-270.
9. Wong T.Z., Fras I.M. PET/CT protocols and practical issues for the evaluation of patients with head and neck cancer. PET Clin 2007, 2(4):413-421.
10. Branstetter B.F., Blodgett T.M., Zimmer L.A., et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone?. Radiology 2005, 235(2):580-586.
11. Jeong H.S., Baek C.H., Son Y.I., et al. Use of integrated 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head Neck 2007, 29(3):203-210.
12. Syed R., Bomanji J.B., Nagabhushan N., et al. Impact of combined (18)F-FDG PET/CT in head and neck tumours. Br J Cancer 2005, 92(6):1046-1050.
13. Higgins K.A., Hoang J.K., Roach M.C., et al. Analysis of pretreatment FDG-PET. Int J Radiat Oncol Biol Phys 2012, 82(2):548-553.
14. Xie P., Li M., Zhao H., et al. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. JCancer Res Clin Oncol 2011, 137(7):1085-1093.
15. Torizuka T., Tanizaki Y., Kanno T., et al. Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol 2009, 192:W156-W160.
16. Schinagl D.A., Span P.N., Oyen W.J., et al. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging 2011, 38(8):1449-1458.
17. Stoeckli S.J., Haerle S.K., Strobel K., et al. Initial staging of the neck in head and neck squamous cell carcinoma: a comparison of CT, PET/CT, and ultrasound-guided fine-needle aspiration cytology. Head Neck 2012, 34(4):469-476.
18. Kyzas P.A., Evangelou E., Denaxa-Kyza D., et al. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. JNatl Cancer Inst 2008, 100(10):712-720.
19. Fleming A.J., Smith S.P., Paul C.M., et al. Impact of[18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007, 117(7):1173-1179.
20. Patz E.F., Lowe V.J., Hoffman J.M., et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993, 188(2):487-490.
21. Hafidh M.A., Lacy P.D., Hughes J.P., et al. Evaluation of the impact of addition of PET to CT and MR scanning in the staging of patients with head and neck carcinomas. Eur Arch Otorhinolaryngol 2006, 263(9):853-859.
22. Yoon D.Y., Hwang H.S., Chang S.K., et al. CT, MR, US, 18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol 2009, 19(3):634-642.
23. Xu G.Z., Zhu X.D., Li M.Y. Accuracy of whole-body PET and PET-CT in initial M staging of head and neck cancer: a meta-analysis. Head Neck 2011, 33:87-94.
24. Gupta T., Master Z., Kannan S., et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011, 38:2083-2209.
25. Andrade R.S., Heron D.E., Degirmenci B., et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006, 65(5):1315-1322.
26. Issing W.J., Taleban B., Tauber S. Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol 2003, 260(8):436-443.
27. Keller F., Psychogios G., Linke R., et al. Carcinoma of unknown primary in the head and neck: comparison between positron emission tomography (PET) and PET/CT. Head Neck 2011, 33(11):1569-1575.
28. Pattani K.M., Goodier M., Lilien D., et al. Utility of panendoscopy for the detection of unknown primary head and neck cancer in patients with a negative PET/CT scan. Ear Nose Throat J 2011, 90(8):E16-E20.
29. Rudmik L., Lau H.Y., Matthews T.W., et al. Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial. Head Neck 2011, 33(7):935-940.
30. Nam S.Y., Roh J.L., Kim J.S., et al. Focal uptake of 18F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol 2007, 67:135-139.
31. Kim B.H., Na M.A., Kim I.J., et al. Risk stratification and prediction of cancer of focal thyroid fluorodeoxyglucose uptake during cancer evaluation. Ann Nucl Med 2010, 24(10):721-728.
32. Eloya J.A., Bretta E.M., Fatterpekara G.M., et al. The significance and management of incidental [18F]fluorodeoxyglucose-positron-emission tomography uptake in the thyroid gland in patients with cancer. AJNR Am J Neuroradiol 2009, 30:1431-1434.
33. Karantanis D., Bogsrud T.V., Wiseman G.A., et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. JNucl Med 2007, 48:896-901.
34. Chen W., Parsons M., Torigian D., et al. Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun 2009, 30(3):240-244.
35. Razfar A., Branstetter B.F., Christopoulos A., et al. Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2010, 136(2):120-125.
36. Mosci C., Iagaru A. PET/CT imaging of thyroid cancer. Clin Nucl Med 2011, 36(12):e180-e185.
37. Roh J.L., Ryu C.H., Choi S.H., et al. Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. JNucl Med 2007, 48(2):240-246.
38. Razfar A., Heron D.E., Branstetter B.F., et al. Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope 2010, 120(4):734-738.
39. Uchida Y., Minoshima S., Kawata T., et al. Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors. Clin Nucl Med 2005, 30(3):170-176.
40. Blodgett T.M., Fukui M.B., Snyderman C.H., et al. Combined PET-CT in the head and neck: part 1. Physiologic, altered physiologic, and artifactual FDG uptake. Radiographics 2005, 25(4):897-912.
41. Hoogsteen I.J., Marres H.A., Bussink J., et al. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck 2007, 29:591-604.
42. Sun A., Sörensen J., Karlsson M., et al. 1-[11C]-acetate PET imaging in head and neck cancer-a comparison with 18F-FDG-PET: implications for staging and radiotherapy planning. Eur J Nucl Med Mol Imaging 2007, 34:651-665.
43. Wang W., Lee N.Y., Georgi J.C., et al. Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer. JNucl Med 2010, 51(1):37-45.
44. Hendrickson K., Phillips M., Smith W., et al. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011, 101(3):369-375.
45. Rajendran J.G., Schwartz D.L., O'Sullivan J., et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006, 12(18):5435-5441.
46. Rischin D., Peters L., Hicks R., et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. JClin Oncol 2001, 19(2):535-542.
47. Troost E.G., Bussink J., Hoffmann A.L., et al. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. JNucl Med 2010, 51(6):866-874.
48. Menda Y., Boles Ponto L.L., Dornfeld K.J., et al. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. JNucl Med 2009, 50(7):1028-1035.
49. Ito K., Yokoyama J., Kubota K., et al. 18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. Eur J Nucl Med Mol Imaging 2010, 37(7):1318-1327.